Author

Cecilia Bergonzini

Leiden UniversityORCID 0000-0002-0789-118XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Elisa GiovannettiiD· 2 shared Alessandro GregoriiD· 1 shared Barbara ParrinoiD· 1 shared Camilla PecoraroiD· 1 shared Daniela CarboneiD· 1 shared Erik H.J. DaneniD· 1 shared Fabio Scianò· 1 shared Francesca Terrana· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

Elisa GiovannettiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Altered Mechanobiology of PDAC Cells with Acquired Chemoresistance to Gemcitabine and Paclitaxel.

Alessandro Gregori, Cecilia Bergonzini, Mjriam Capula, Rick Rodrigues de Mercado, Erik H.J. Danen, Elisa Giovannetti, Thomas Schmidt

This study investigates altered mechanobiology in PDAC cells with acquired chemoresistance to gemcitabine and paclitaxel, finding increased traction forces and altered motility and invasion.

Cancers · Nov 18, 2024Peer-reviewedBiophysics

Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: Synthesis, mechanistic Insights and promising antitumor and safety profile

Camilla Pecoraro, Daniela Carbone, Fabio Scianò, Francesca Terrana, Geng Xu, Cecilia Bergonzini, Margot S. F. Roeten, Stella Cascioferro, Girolamo Cirrincione, Patrizia Diana, Elisa Giovannetti, Barbara Parrino

This study identifies compound 10l as a potent FAK inhibitor with antitumor activity and safety in pancreatic cancer models.

Journal of drug targeting · Jul 27, 2024Peer-reviewedCancer Biology